nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—AOX1—Raloxifene—breast cancer	0.452	0.788	CbGbCtD
Brimonidine—AOX1—Methotrexate—breast cancer	0.121	0.212	CbGbCtD
Brimonidine—AOX1—nipple—breast cancer	0.00193	0.0911	CbGeAlD
Brimonidine—ADRA2C—nipple—breast cancer	0.00122	0.0576	CbGeAlD
Brimonidine—AOX1—endometrium—breast cancer	0.00117	0.055	CbGeAlD
Brimonidine—AOX1—uterus—breast cancer	0.00107	0.0507	CbGeAlD
Brimonidine—AOX1—pituitary gland—breast cancer	0.00105	0.0498	CbGeAlD
Brimonidine—AOX1—adipose tissue—breast cancer	0.00105	0.0496	CbGeAlD
Brimonidine—ADRA2A—nipple—breast cancer	0.000974	0.046	CbGeAlD
Brimonidine—AOX1—female reproductive system—breast cancer	0.000966	0.0456	CbGeAlD
Brimonidine—AOX1—adrenal gland—breast cancer	0.000942	0.0445	CbGeAlD
Brimonidine—AOX1—female gonad—breast cancer	0.000879	0.0415	CbGeAlD
Brimonidine—AOX1—endocrine gland—breast cancer	0.000817	0.0386	CbGeAlD
Brimonidine—ADRA2C—endometrium—breast cancer	0.000737	0.0348	CbGeAlD
Brimonidine—ADRA2C—uterus—breast cancer	0.000679	0.032	CbGeAlD
Brimonidine—ADRA2C—pituitary gland—breast cancer	0.000667	0.0315	CbGeAlD
Brimonidine—ADRA2C—adipose tissue—breast cancer	0.000664	0.0313	CbGeAlD
Brimonidine—Clonidine—CYP1A1—breast cancer	0.000629	0.343	CrCbGaD
Brimonidine—ADRA2C—adrenal gland—breast cancer	0.000596	0.0281	CbGeAlD
Brimonidine—ADRA2A—endometrium—breast cancer	0.000588	0.0278	CbGeAlD
Brimonidine—AOX1—lymph node—breast cancer	0.000565	0.0267	CbGeAlD
Brimonidine—ADRA2C—female gonad—breast cancer	0.000555	0.0262	CbGeAlD
Brimonidine—ADRA2A—uterus—breast cancer	0.000542	0.0256	CbGeAlD
Brimonidine—ADRA2A—pituitary gland—breast cancer	0.000532	0.0251	CbGeAlD
Brimonidine—ADRA2A—adipose tissue—breast cancer	0.00053	0.025	CbGeAlD
Brimonidine—ADRA2A—female reproductive system—breast cancer	0.000487	0.023	CbGeAlD
Brimonidine—ADRA2A—adrenal gland—breast cancer	0.000475	0.0224	CbGeAlD
Brimonidine—Clonidine—CYP2D6—breast cancer	0.000468	0.255	CrCbGaD
Brimonidine—ADRA2A—female gonad—breast cancer	0.000443	0.0209	CbGeAlD
Brimonidine—ADRA2A—endocrine gland—breast cancer	0.000412	0.0195	CbGeAlD
Brimonidine—Clonidine—CYP3A4—breast cancer	0.000401	0.219	CrCbGaD
Brimonidine—ADRA2C—lymph node—breast cancer	0.000357	0.0169	CbGeAlD
Brimonidine—Clonidine—ABCB1—breast cancer	0.000334	0.182	CrCbGaD
Brimonidine—ADRA2A—lymph node—breast cancer	0.000285	0.0134	CbGeAlD
Brimonidine—Dermatitis—Thiotepa—breast cancer	0.000109	0.000346	CcSEcCtD
Brimonidine—Dyspnoea—Paclitaxel—breast cancer	0.000109	0.000345	CcSEcCtD
Brimonidine—Headache—Thiotepa—breast cancer	0.000109	0.000344	CcSEcCtD
Brimonidine—Somnolence—Paclitaxel—breast cancer	0.000109	0.000344	CcSEcCtD
Brimonidine—Palpitations—Capecitabine—breast cancer	0.000108	0.000343	CcSEcCtD
Brimonidine—Chest pain—Docetaxel—breast cancer	0.000108	0.000342	CcSEcCtD
Brimonidine—Myalgia—Docetaxel—breast cancer	0.000108	0.000342	CcSEcCtD
Brimonidine—Arthralgia—Docetaxel—breast cancer	0.000108	0.000342	CcSEcCtD
Brimonidine—Loss of consciousness—Capecitabine—breast cancer	0.000108	0.000342	CcSEcCtD
Brimonidine—Nausea—Vinorelbine—breast cancer	0.000108	0.000341	CcSEcCtD
Brimonidine—Dyspepsia—Paclitaxel—breast cancer	0.000107	0.00034	CcSEcCtD
Brimonidine—Asthenia—Mitoxantrone—breast cancer	0.000107	0.00034	CcSEcCtD
Brimonidine—Asthenia—Irinotecan—breast cancer	0.000107	0.00034	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	0.000107	0.000339	CcSEcCtD
Brimonidine—Cough—Capecitabine—breast cancer	0.000107	0.000339	CcSEcCtD
Brimonidine—Conjunctivitis—Epirubicin—breast cancer	0.000106	0.000337	CcSEcCtD
Brimonidine—Hypertension—Capecitabine—breast cancer	0.000106	0.000335	CcSEcCtD
Brimonidine—Hypersensitivity—Fluorouracil—breast cancer	0.000106	0.000334	CcSEcCtD
Brimonidine—Dry mouth—Docetaxel—breast cancer	0.000106	0.000334	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000105	0.000334	CcSEcCtD
Brimonidine—Fatigue—Paclitaxel—breast cancer	0.000105	0.000333	CcSEcCtD
Brimonidine—Asthenia—Gemcitabine—breast cancer	0.000105	0.000331	CcSEcCtD
Brimonidine—Arthralgia—Capecitabine—breast cancer	0.000104	0.000331	CcSEcCtD
Brimonidine—Chest pain—Capecitabine—breast cancer	0.000104	0.000331	CcSEcCtD
Brimonidine—Myalgia—Capecitabine—breast cancer	0.000104	0.000331	CcSEcCtD
Brimonidine—Pain—Paclitaxel—breast cancer	0.000104	0.00033	CcSEcCtD
Brimonidine—Pharyngitis—Methotrexate—breast cancer	0.000104	0.00033	CcSEcCtD
Brimonidine—Anxiety—Capecitabine—breast cancer	0.000104	0.00033	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.000104	0.000329	CcSEcCtD
Brimonidine—Oedema—Docetaxel—breast cancer	0.000103	0.000328	CcSEcCtD
Brimonidine—Discomfort—Capecitabine—breast cancer	0.000103	0.000327	CcSEcCtD
Brimonidine—Pruritus—Gemcitabine—breast cancer	0.000103	0.000327	CcSEcCtD
Brimonidine—Nausea—Thiotepa—breast cancer	0.000103	0.000326	CcSEcCtD
Brimonidine—Infection—Docetaxel—breast cancer	0.000103	0.000325	CcSEcCtD
Brimonidine—Sinusitis—Epirubicin—breast cancer	0.000103	0.000325	CcSEcCtD
Brimonidine—Dry mouth—Capecitabine—breast cancer	0.000102	0.000324	CcSEcCtD
Brimonidine—Shock—Docetaxel—breast cancer	0.000102	0.000322	CcSEcCtD
Brimonidine—Nervous system disorder—Docetaxel—breast cancer	0.000101	0.000321	CcSEcCtD
Brimonidine—Pruritus—Fluorouracil—breast cancer	0.000101	0.000321	CcSEcCtD
Brimonidine—Drowsiness—Doxorubicin—breast cancer	0.000101	0.000321	CcSEcCtD
Brimonidine—Visual impairment—Methotrexate—breast cancer	0.000101	0.00032	CcSEcCtD
Brimonidine—Tachycardia—Docetaxel—breast cancer	0.000101	0.00032	CcSEcCtD
Brimonidine—Skin disorder—Docetaxel—breast cancer	0.0001	0.000318	CcSEcCtD
Brimonidine—Oedema—Capecitabine—breast cancer	0.0001	0.000317	CcSEcCtD
Brimonidine—Bradycardia—Epirubicin—breast cancer	0.0001	0.000317	CcSEcCtD
Brimonidine—Infection—Capecitabine—breast cancer	9.95e-05	0.000315	CcSEcCtD
Brimonidine—Dizziness—Irinotecan—breast cancer	9.9e-05	0.000313	CcSEcCtD
Brimonidine—Shock—Capecitabine—breast cancer	9.86e-05	0.000312	CcSEcCtD
Brimonidine—Rhinitis—Epirubicin—breast cancer	9.85e-05	0.000312	CcSEcCtD
Brimonidine—Conjunctivitis—Doxorubicin—breast cancer	9.84e-05	0.000312	CcSEcCtD
Brimonidine—Nervous system disorder—Capecitabine—breast cancer	9.82e-05	0.000311	CcSEcCtD
Brimonidine—Eye disorder—Methotrexate—breast cancer	9.81e-05	0.000311	CcSEcCtD
Brimonidine—Tachycardia—Capecitabine—breast cancer	9.78e-05	0.000309	CcSEcCtD
Brimonidine—Pharyngitis—Epirubicin—breast cancer	9.75e-05	0.000309	CcSEcCtD
Brimonidine—Cardiac disorder—Methotrexate—breast cancer	9.74e-05	0.000308	CcSEcCtD
Brimonidine—Skin disorder—Capecitabine—breast cancer	9.73e-05	0.000308	CcSEcCtD
Brimonidine—Hypotension—Docetaxel—breast cancer	9.67e-05	0.000306	CcSEcCtD
Brimonidine—Angiopathy—Methotrexate—breast cancer	9.52e-05	0.000301	CcSEcCtD
Brimonidine—Sinusitis—Doxorubicin—breast cancer	9.5e-05	0.000301	CcSEcCtD
Brimonidine—Immune system disorder—Methotrexate—breast cancer	9.48e-05	0.0003	CcSEcCtD
Brimonidine—Dizziness—Fluorouracil—breast cancer	9.48e-05	0.0003	CcSEcCtD
Brimonidine—Visual impairment—Epirubicin—breast cancer	9.47e-05	0.0003	CcSEcCtD
Brimonidine—Mediastinal disorder—Methotrexate—breast cancer	9.46e-05	0.000299	CcSEcCtD
Brimonidine—Rash—Irinotecan—breast cancer	9.44e-05	0.000299	CcSEcCtD
Brimonidine—Rash—Mitoxantrone—breast cancer	9.44e-05	0.000299	CcSEcCtD
Brimonidine—Dermatitis—Irinotecan—breast cancer	9.43e-05	0.000298	CcSEcCtD
Brimonidine—Dermatitis—Mitoxantrone—breast cancer	9.43e-05	0.000298	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Docetaxel—breast cancer	9.43e-05	0.000298	CcSEcCtD
Brimonidine—Headache—Irinotecan—breast cancer	9.38e-05	0.000297	CcSEcCtD
Brimonidine—Headache—Mitoxantrone—breast cancer	9.38e-05	0.000297	CcSEcCtD
Brimonidine—Hypotension—Capecitabine—breast cancer	9.36e-05	0.000296	CcSEcCtD
Brimonidine—Insomnia—Docetaxel—breast cancer	9.36e-05	0.000296	CcSEcCtD
Brimonidine—Paraesthesia—Docetaxel—breast cancer	9.29e-05	0.000294	CcSEcCtD
Brimonidine—Bradycardia—Doxorubicin—breast cancer	9.25e-05	0.000293	CcSEcCtD
Brimonidine—Dyspnoea—Docetaxel—breast cancer	9.22e-05	0.000292	CcSEcCtD
Brimonidine—Somnolence—Docetaxel—breast cancer	9.2e-05	0.000291	CcSEcCtD
Brimonidine—Mental disorder—Methotrexate—breast cancer	9.2e-05	0.000291	CcSEcCtD
Brimonidine—Rash—Gemcitabine—breast cancer	9.19e-05	0.000291	CcSEcCtD
Brimonidine—Dermatitis—Gemcitabine—breast cancer	9.18e-05	0.000291	CcSEcCtD
Brimonidine—Eye disorder—Epirubicin—breast cancer	9.18e-05	0.000291	CcSEcCtD
Brimonidine—Erythema—Methotrexate—breast cancer	9.14e-05	0.000289	CcSEcCtD
Brimonidine—Headache—Gemcitabine—breast cancer	9.13e-05	0.000289	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Capecitabine—breast cancer	9.13e-05	0.000289	CcSEcCtD
Brimonidine—Cardiac disorder—Epirubicin—breast cancer	9.12e-05	0.000289	CcSEcCtD
Brimonidine—Flushing—Epirubicin—breast cancer	9.12e-05	0.000289	CcSEcCtD
Brimonidine—Rhinitis—Doxorubicin—breast cancer	9.11e-05	0.000288	CcSEcCtD
Brimonidine—Dyspepsia—Docetaxel—breast cancer	9.11e-05	0.000288	CcSEcCtD
Brimonidine—Insomnia—Capecitabine—breast cancer	9.06e-05	0.000287	CcSEcCtD
Brimonidine—Rash—Fluorouracil—breast cancer	9.04e-05	0.000286	CcSEcCtD
Brimonidine—Dermatitis—Fluorouracil—breast cancer	9.03e-05	0.000286	CcSEcCtD
Brimonidine—Pharyngitis—Doxorubicin—breast cancer	9.02e-05	0.000286	CcSEcCtD
Brimonidine—Paraesthesia—Capecitabine—breast cancer	8.99e-05	0.000285	CcSEcCtD
Brimonidine—Hypersensitivity—Paclitaxel—breast cancer	8.99e-05	0.000285	CcSEcCtD
Brimonidine—Headache—Fluorouracil—breast cancer	8.98e-05	0.000284	CcSEcCtD
Brimonidine—Dysgeusia—Methotrexate—breast cancer	8.95e-05	0.000283	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Docetaxel—breast cancer	8.93e-05	0.000283	CcSEcCtD
Brimonidine—Dyspnoea—Capecitabine—breast cancer	8.93e-05	0.000283	CcSEcCtD
Brimonidine—Fatigue—Docetaxel—breast cancer	8.92e-05	0.000282	CcSEcCtD
Brimonidine—Angiopathy—Epirubicin—breast cancer	8.91e-05	0.000282	CcSEcCtD
Brimonidine—Nausea—Irinotecan—breast cancer	8.89e-05	0.000281	CcSEcCtD
Brimonidine—Nausea—Mitoxantrone—breast cancer	8.89e-05	0.000281	CcSEcCtD
Brimonidine—Immune system disorder—Epirubicin—breast cancer	8.87e-05	0.000281	CcSEcCtD
Brimonidine—Mediastinal disorder—Epirubicin—breast cancer	8.85e-05	0.00028	CcSEcCtD
Brimonidine—Pain—Docetaxel—breast cancer	8.85e-05	0.00028	CcSEcCtD
Brimonidine—Dyspepsia—Capecitabine—breast cancer	8.82e-05	0.000279	CcSEcCtD
Brimonidine—Arrhythmia—Epirubicin—breast cancer	8.77e-05	0.000278	CcSEcCtD
Brimonidine—Visual impairment—Doxorubicin—breast cancer	8.76e-05	0.000277	CcSEcCtD
Brimonidine—Asthenia—Paclitaxel—breast cancer	8.76e-05	0.000277	CcSEcCtD
Brimonidine—Nausea—Gemcitabine—breast cancer	8.66e-05	0.000274	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Capecitabine—breast cancer	8.65e-05	0.000274	CcSEcCtD
Brimonidine—Fatigue—Capecitabine—breast cancer	8.64e-05	0.000273	CcSEcCtD
Brimonidine—Pruritus—Paclitaxel—breast cancer	8.64e-05	0.000273	CcSEcCtD
Brimonidine—Vision blurred—Methotrexate—breast cancer	8.61e-05	0.000273	CcSEcCtD
Brimonidine—Mental disorder—Epirubicin—breast cancer	8.61e-05	0.000272	CcSEcCtD
Brimonidine—Pain—Capecitabine—breast cancer	8.57e-05	0.000271	CcSEcCtD
Brimonidine—Erythema—Epirubicin—breast cancer	8.55e-05	0.000271	CcSEcCtD
Brimonidine—Nausea—Fluorouracil—breast cancer	8.51e-05	0.00027	CcSEcCtD
Brimonidine—Eye disorder—Doxorubicin—breast cancer	8.49e-05	0.000269	CcSEcCtD
Brimonidine—Cardiac disorder—Doxorubicin—breast cancer	8.44e-05	0.000267	CcSEcCtD
Brimonidine—Flushing—Doxorubicin—breast cancer	8.44e-05	0.000267	CcSEcCtD
Brimonidine—Dysgeusia—Epirubicin—breast cancer	8.37e-05	0.000265	CcSEcCtD
Brimonidine—Angiopathy—Doxorubicin—breast cancer	8.25e-05	0.000261	CcSEcCtD
Brimonidine—Immune system disorder—Doxorubicin—breast cancer	8.21e-05	0.00026	CcSEcCtD
Brimonidine—Mediastinal disorder—Doxorubicin—breast cancer	8.19e-05	0.000259	CcSEcCtD
Brimonidine—Arrhythmia—Doxorubicin—breast cancer	8.12e-05	0.000257	CcSEcCtD
Brimonidine—Dizziness—Paclitaxel—breast cancer	8.07e-05	0.000256	CcSEcCtD
Brimonidine—Vision blurred—Epirubicin—breast cancer	8.06e-05	0.000255	CcSEcCtD
Brimonidine—Cough—Methotrexate—breast cancer	7.97e-05	0.000252	CcSEcCtD
Brimonidine—Mental disorder—Doxorubicin—breast cancer	7.96e-05	0.000252	CcSEcCtD
Brimonidine—Erythema—Doxorubicin—breast cancer	7.91e-05	0.00025	CcSEcCtD
Brimonidine—Chest pain—Methotrexate—breast cancer	7.78e-05	0.000246	CcSEcCtD
Brimonidine—Arthralgia—Methotrexate—breast cancer	7.78e-05	0.000246	CcSEcCtD
Brimonidine—Myalgia—Methotrexate—breast cancer	7.78e-05	0.000246	CcSEcCtD
Brimonidine—Dysgeusia—Doxorubicin—breast cancer	7.75e-05	0.000245	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	7.73e-05	0.000245	CcSEcCtD
Brimonidine—Rash—Paclitaxel—breast cancer	7.7e-05	0.000244	CcSEcCtD
Brimonidine—Dermatitis—Paclitaxel—breast cancer	7.69e-05	0.000243	CcSEcCtD
Brimonidine—Discomfort—Methotrexate—breast cancer	7.69e-05	0.000243	CcSEcCtD
Brimonidine—Syncope—Epirubicin—breast cancer	7.67e-05	0.000243	CcSEcCtD
Brimonidine—Headache—Paclitaxel—breast cancer	7.65e-05	0.000242	CcSEcCtD
Brimonidine—Hypersensitivity—Docetaxel—breast cancer	7.62e-05	0.000241	CcSEcCtD
Brimonidine—Palpitations—Epirubicin—breast cancer	7.56e-05	0.000239	CcSEcCtD
Brimonidine—Loss of consciousness—Epirubicin—breast cancer	7.52e-05	0.000238	CcSEcCtD
Brimonidine—Cough—Epirubicin—breast cancer	7.46e-05	0.000236	CcSEcCtD
Brimonidine—Vision blurred—Doxorubicin—breast cancer	7.46e-05	0.000236	CcSEcCtD
Brimonidine—Asthenia—Docetaxel—breast cancer	7.42e-05	0.000235	CcSEcCtD
Brimonidine—Infection—Methotrexate—breast cancer	7.41e-05	0.000235	CcSEcCtD
Brimonidine—Hypertension—Epirubicin—breast cancer	7.38e-05	0.000234	CcSEcCtD
Brimonidine—Hypersensitivity—Capecitabine—breast cancer	7.38e-05	0.000234	CcSEcCtD
Brimonidine—Pruritus—Docetaxel—breast cancer	7.32e-05	0.000232	CcSEcCtD
Brimonidine—Nervous system disorder—Methotrexate—breast cancer	7.31e-05	0.000232	CcSEcCtD
Brimonidine—Arthralgia—Epirubicin—breast cancer	7.28e-05	0.00023	CcSEcCtD
Brimonidine—Chest pain—Epirubicin—breast cancer	7.28e-05	0.00023	CcSEcCtD
Brimonidine—Myalgia—Epirubicin—breast cancer	7.28e-05	0.00023	CcSEcCtD
Brimonidine—Anxiety—Epirubicin—breast cancer	7.25e-05	0.00023	CcSEcCtD
Brimonidine—Nausea—Paclitaxel—breast cancer	7.25e-05	0.00023	CcSEcCtD
Brimonidine—Skin disorder—Methotrexate—breast cancer	7.24e-05	0.000229	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	7.23e-05	0.000229	CcSEcCtD
Brimonidine—Discomfort—Epirubicin—breast cancer	7.19e-05	0.000228	CcSEcCtD
Brimonidine—Asthenia—Capecitabine—breast cancer	7.19e-05	0.000228	CcSEcCtD
Brimonidine—Dry mouth—Epirubicin—breast cancer	7.12e-05	0.000225	CcSEcCtD
Brimonidine—Syncope—Doxorubicin—breast cancer	7.1e-05	0.000225	CcSEcCtD
Brimonidine—Pruritus—Capecitabine—breast cancer	7.09e-05	0.000224	CcSEcCtD
Brimonidine—Palpitations—Doxorubicin—breast cancer	6.99e-05	0.000221	CcSEcCtD
Brimonidine—Oedema—Epirubicin—breast cancer	6.98e-05	0.000221	CcSEcCtD
Brimonidine—Hypotension—Methotrexate—breast cancer	6.97e-05	0.000221	CcSEcCtD
Brimonidine—Loss of consciousness—Doxorubicin—breast cancer	6.95e-05	0.00022	CcSEcCtD
Brimonidine—Infection—Epirubicin—breast cancer	6.93e-05	0.000219	CcSEcCtD
Brimonidine—Cough—Doxorubicin—breast cancer	6.9e-05	0.000219	CcSEcCtD
Brimonidine—Shock—Epirubicin—breast cancer	6.87e-05	0.000217	CcSEcCtD
Brimonidine—Nervous system disorder—Epirubicin—breast cancer	6.84e-05	0.000217	CcSEcCtD
Brimonidine—Dizziness—Docetaxel—breast cancer	6.84e-05	0.000217	CcSEcCtD
Brimonidine—Hypertension—Doxorubicin—breast cancer	6.83e-05	0.000216	CcSEcCtD
Brimonidine—Tachycardia—Epirubicin—breast cancer	6.81e-05	0.000216	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Methotrexate—breast cancer	6.79e-05	0.000215	CcSEcCtD
Brimonidine—Skin disorder—Epirubicin—breast cancer	6.78e-05	0.000215	CcSEcCtD
Brimonidine—Insomnia—Methotrexate—breast cancer	6.74e-05	0.000214	CcSEcCtD
Brimonidine—Myalgia—Doxorubicin—breast cancer	6.74e-05	0.000213	CcSEcCtD
Brimonidine—Chest pain—Doxorubicin—breast cancer	6.74e-05	0.000213	CcSEcCtD
Brimonidine—Arthralgia—Doxorubicin—breast cancer	6.74e-05	0.000213	CcSEcCtD
Brimonidine—Anxiety—Doxorubicin—breast cancer	6.71e-05	0.000212	CcSEcCtD
Brimonidine—Paraesthesia—Methotrexate—breast cancer	6.7e-05	0.000212	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	6.69e-05	0.000212	CcSEcCtD
Brimonidine—Discomfort—Doxorubicin—breast cancer	6.66e-05	0.000211	CcSEcCtD
Brimonidine—Dyspnoea—Methotrexate—breast cancer	6.65e-05	0.00021	CcSEcCtD
Brimonidine—Somnolence—Methotrexate—breast cancer	6.63e-05	0.00021	CcSEcCtD
Brimonidine—Dizziness—Capecitabine—breast cancer	6.62e-05	0.00021	CcSEcCtD
Brimonidine—Dry mouth—Doxorubicin—breast cancer	6.59e-05	0.000209	CcSEcCtD
Brimonidine—Dyspepsia—Methotrexate—breast cancer	6.56e-05	0.000208	CcSEcCtD
Brimonidine—Rash—Docetaxel—breast cancer	6.52e-05	0.000207	CcSEcCtD
Brimonidine—Hypotension—Epirubicin—breast cancer	6.52e-05	0.000206	CcSEcCtD
Brimonidine—Dermatitis—Docetaxel—breast cancer	6.52e-05	0.000206	CcSEcCtD
Brimonidine—Headache—Docetaxel—breast cancer	6.48e-05	0.000205	CcSEcCtD
Brimonidine—Oedema—Doxorubicin—breast cancer	6.46e-05	0.000204	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Methotrexate—breast cancer	6.44e-05	0.000204	CcSEcCtD
Brimonidine—Fatigue—Methotrexate—breast cancer	6.43e-05	0.000204	CcSEcCtD
Brimonidine—Infection—Doxorubicin—breast cancer	6.41e-05	0.000203	CcSEcCtD
Brimonidine—Pain—Methotrexate—breast cancer	6.38e-05	0.000202	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Epirubicin—breast cancer	6.36e-05	0.000201	CcSEcCtD
Brimonidine—Shock—Doxorubicin—breast cancer	6.35e-05	0.000201	CcSEcCtD
Brimonidine—Nervous system disorder—Doxorubicin—breast cancer	6.33e-05	0.0002	CcSEcCtD
Brimonidine—Rash—Capecitabine—breast cancer	6.32e-05	0.0002	CcSEcCtD
Brimonidine—Insomnia—Epirubicin—breast cancer	6.31e-05	0.0002	CcSEcCtD
Brimonidine—Dermatitis—Capecitabine—breast cancer	6.31e-05	0.0002	CcSEcCtD
Brimonidine—Tachycardia—Doxorubicin—breast cancer	6.3e-05	0.0002	CcSEcCtD
Brimonidine—Headache—Capecitabine—breast cancer	6.28e-05	0.000199	CcSEcCtD
Brimonidine—Skin disorder—Doxorubicin—breast cancer	6.27e-05	0.000199	CcSEcCtD
Brimonidine—Paraesthesia—Epirubicin—breast cancer	6.27e-05	0.000198	CcSEcCtD
Brimonidine—Dyspnoea—Epirubicin—breast cancer	6.22e-05	0.000197	CcSEcCtD
Brimonidine—Somnolence—Epirubicin—breast cancer	6.2e-05	0.000196	CcSEcCtD
Brimonidine—Nausea—Docetaxel—breast cancer	6.15e-05	0.000195	CcSEcCtD
Brimonidine—Dyspepsia—Epirubicin—breast cancer	6.14e-05	0.000194	CcSEcCtD
Brimonidine—Hypotension—Doxorubicin—breast cancer	6.03e-05	0.000191	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Epirubicin—breast cancer	6.02e-05	0.000191	CcSEcCtD
Brimonidine—Fatigue—Epirubicin—breast cancer	6.02e-05	0.00019	CcSEcCtD
Brimonidine—Pain—Epirubicin—breast cancer	5.97e-05	0.000189	CcSEcCtD
Brimonidine—Nausea—Capecitabine—breast cancer	5.95e-05	0.000188	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Doxorubicin—breast cancer	5.88e-05	0.000186	CcSEcCtD
Brimonidine—Insomnia—Doxorubicin—breast cancer	5.84e-05	0.000185	CcSEcCtD
Brimonidine—Paraesthesia—Doxorubicin—breast cancer	5.8e-05	0.000184	CcSEcCtD
Brimonidine—Dyspnoea—Doxorubicin—breast cancer	5.76e-05	0.000182	CcSEcCtD
Brimonidine—Somnolence—Doxorubicin—breast cancer	5.74e-05	0.000182	CcSEcCtD
Brimonidine—Dyspepsia—Doxorubicin—breast cancer	5.68e-05	0.00018	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Doxorubicin—breast cancer	5.57e-05	0.000176	CcSEcCtD
Brimonidine—Fatigue—Doxorubicin—breast cancer	5.57e-05	0.000176	CcSEcCtD
Brimonidine—Pain—Doxorubicin—breast cancer	5.52e-05	0.000175	CcSEcCtD
Brimonidine—Hypersensitivity—Methotrexate—breast cancer	5.49e-05	0.000174	CcSEcCtD
Brimonidine—Asthenia—Methotrexate—breast cancer	5.35e-05	0.000169	CcSEcCtD
Brimonidine—Pruritus—Methotrexate—breast cancer	5.28e-05	0.000167	CcSEcCtD
Brimonidine—Hypersensitivity—Epirubicin—breast cancer	5.14e-05	0.000163	CcSEcCtD
Brimonidine—Asthenia—Epirubicin—breast cancer	5.01e-05	0.000159	CcSEcCtD
Brimonidine—Pruritus—Epirubicin—breast cancer	4.94e-05	0.000156	CcSEcCtD
Brimonidine—Dizziness—Methotrexate—breast cancer	4.93e-05	0.000156	CcSEcCtD
Brimonidine—Hypersensitivity—Doxorubicin—breast cancer	4.76e-05	0.000151	CcSEcCtD
Brimonidine—Rash—Methotrexate—breast cancer	4.7e-05	0.000149	CcSEcCtD
Brimonidine—Dermatitis—Methotrexate—breast cancer	4.7e-05	0.000149	CcSEcCtD
Brimonidine—Headache—Methotrexate—breast cancer	4.67e-05	0.000148	CcSEcCtD
Brimonidine—Asthenia—Doxorubicin—breast cancer	4.63e-05	0.000147	CcSEcCtD
Brimonidine—Dizziness—Epirubicin—breast cancer	4.61e-05	0.000146	CcSEcCtD
Brimonidine—Pruritus—Doxorubicin—breast cancer	4.57e-05	0.000145	CcSEcCtD
Brimonidine—Nausea—Methotrexate—breast cancer	4.43e-05	0.00014	CcSEcCtD
Brimonidine—Rash—Epirubicin—breast cancer	4.4e-05	0.000139	CcSEcCtD
Brimonidine—Dermatitis—Epirubicin—breast cancer	4.4e-05	0.000139	CcSEcCtD
Brimonidine—Headache—Epirubicin—breast cancer	4.37e-05	0.000138	CcSEcCtD
Brimonidine—Dizziness—Doxorubicin—breast cancer	4.27e-05	0.000135	CcSEcCtD
Brimonidine—Nausea—Epirubicin—breast cancer	4.15e-05	0.000131	CcSEcCtD
Brimonidine—Rash—Doxorubicin—breast cancer	4.07e-05	0.000129	CcSEcCtD
Brimonidine—Dermatitis—Doxorubicin—breast cancer	4.07e-05	0.000129	CcSEcCtD
Brimonidine—Headache—Doxorubicin—breast cancer	4.05e-05	0.000128	CcSEcCtD
Brimonidine—Nausea—Doxorubicin—breast cancer	3.84e-05	0.000121	CcSEcCtD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CB—breast cancer	1.28e-05	0.000146	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ADAM10—breast cancer	1.27e-05	0.000145	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STK11—breast cancer	1.27e-05	0.000145	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PIK3CA—breast cancer	1.26e-05	0.000144	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL2—breast cancer	1.26e-05	0.000143	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—HRAS—breast cancer	1.26e-05	0.000143	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PLG—breast cancer	1.26e-05	0.000143	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TERT—breast cancer	1.25e-05	0.000143	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AKT2—breast cancer	1.24e-05	0.000141	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GPX1—breast cancer	1.24e-05	0.000141	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SPP1—breast cancer	1.24e-05	0.000141	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FGF10—breast cancer	1.24e-05	0.000141	CbGpPWpGaD
Brimonidine—AOX1—Disease—AKT1—breast cancer	1.23e-05	0.00014	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CXCL8—breast cancer	1.23e-05	0.00014	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP1A1—breast cancer	1.22e-05	0.000139	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ERBB3—breast cancer	1.22e-05	0.000139	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FGFR2—breast cancer	1.22e-05	0.000139	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FGFR1—breast cancer	1.22e-05	0.000139	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ERCC2—breast cancer	1.21e-05	0.000138	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—KRAS—breast cancer	1.2e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HIF1A—breast cancer	1.2e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CD—breast cancer	1.19e-05	0.000136	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PDGFA—breast cancer	1.19e-05	0.000136	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—AKT1—breast cancer	1.19e-05	0.000135	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CG—breast cancer	1.18e-05	0.000134	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL2—breast cancer	1.18e-05	0.000134	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TGFBR2—breast cancer	1.18e-05	0.000134	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TERT—breast cancer	1.17e-05	0.000133	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—LEP—breast cancer	1.17e-05	0.000133	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CAV1—breast cancer	1.16e-05	0.000132	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ITPR1—breast cancer	1.16e-05	0.000132	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MMP3—breast cancer	1.15e-05	0.000131	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ERBB4—breast cancer	1.15e-05	0.000131	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STAT5A—breast cancer	1.15e-05	0.000131	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KDR—breast cancer	1.15e-05	0.000131	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CB—breast cancer	1.15e-05	0.00013	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—MTHFR—breast cancer	1.14e-05	0.00013	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FGFR1—breast cancer	1.14e-05	0.00013	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HIF1A—breast cancer	1.12e-05	0.000128	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ESR1—breast cancer	1.12e-05	0.000127	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SMAD4—breast cancer	1.11e-05	0.000127	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—AKT1—breast cancer	1.11e-05	0.000127	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IGF1R—breast cancer	1.11e-05	0.000126	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—PIK3CA—breast cancer	1.11e-05	0.000126	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FN1—breast cancer	1.1e-05	0.000126	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CXCL8—breast cancer	1.1e-05	0.000125	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—LEP—breast cancer	1.09e-05	0.000125	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NFKBIA—breast cancer	1.09e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HES1—breast cancer	1.09e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CAV1—breast cancer	1.08e-05	0.000123	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NOTCH1—breast cancer	1.08e-05	0.000123	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PLA2G4A—breast cancer	1.08e-05	0.000123	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NCOR1—breast cancer	1.08e-05	0.000123	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KDR—breast cancer	1.07e-05	0.000122	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TP53—breast cancer	1.07e-05	0.000122	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CSF2—breast cancer	1.07e-05	0.000122	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FGF1—breast cancer	1.07e-05	0.000122	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—RAF1—breast cancer	1.07e-05	0.000121	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NRG1—breast cancer	1.06e-05	0.000121	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—APC—breast cancer	1.06e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CG—breast cancer	1.06e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KIT—breast cancer	1.06e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CAV1—breast cancer	1.05e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—H2AFX—breast cancer	1.05e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—IL2—breast cancer	1.05e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—E2F1—breast cancer	1.05e-05	0.000119	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EGF—breast cancer	1.04e-05	0.000119	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ESR1—breast cancer	1.04e-05	0.000119	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CB—breast cancer	1.04e-05	0.000118	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CD—breast cancer	1.04e-05	0.000118	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—AKT1—breast cancer	1.03e-05	0.000118	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FN1—breast cancer	1.03e-05	0.000117	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ALB—breast cancer	1.02e-05	0.000117	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—HRAS—breast cancer	1.02e-05	0.000116	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NFKBIA—breast cancer	1.02e-05	0.000116	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—MAPK3—breast cancer	1.01e-05	0.000115	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NOTCH1—breast cancer	1.01e-05	0.000115	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SPP1—breast cancer	1e-05	0.000114	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CXCL8—breast cancer	1e-05	0.000114	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—BRAF—breast cancer	9.94e-06	0.000113	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ERBB3—breast cancer	9.93e-06	0.000113	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FGFR2—breast cancer	9.92e-06	0.000113	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CG—breast cancer	9.88e-06	0.000112	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—APC—breast cancer	9.88e-06	0.000112	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KIT—breast cancer	9.88e-06	0.000112	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—NOS3—breast cancer	9.8e-06	0.000112	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EGF—breast cancer	9.76e-06	0.000111	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IGF1—breast cancer	9.68e-06	0.00011	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AKT2—breast cancer	9.67e-06	0.00011	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—EGFR—breast cancer	9.63e-06	0.00011	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CG—breast cancer	9.59e-06	0.000109	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL2—breast cancer	9.55e-06	0.000109	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TERT—breast cancer	9.52e-06	0.000108	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—MAPK3—breast cancer	9.46e-06	0.000108	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CD—breast cancer	9.29e-06	0.000106	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—BRAF—breast cancer	9.28e-06	0.000106	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FGFR1—breast cancer	9.24e-06	0.000105	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—PIK3CA—breast cancer	9.21e-06	0.000105	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SERPINE1—breast cancer	9.19e-06	0.000105	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HIF1A—breast cancer	9.1e-06	0.000104	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—KRAS—breast cancer	9.1e-06	0.000104	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CB—breast cancer	9.05e-06	0.000103	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IGF1—breast cancer	9.04e-06	0.000103	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AKT2—breast cancer	9.04e-06	0.000103	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—AKT1—breast cancer	9.03e-06	0.000103	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—EGFR—breast cancer	9e-06	0.000102	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PTGS2—breast cancer	8.97e-06	0.000102	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—LEP—breast cancer	8.89e-06	0.000101	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CAV1—breast cancer	8.81e-06	0.0001	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NOS3—breast cancer	8.78e-06	9.99e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KDR—breast cancer	8.71e-06	9.91e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CD—breast cancer	8.68e-06	9.88e-05	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PIK3CA—breast cancer	8.6e-06	9.79e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SERPINE1—breast cancer	8.59e-06	9.77e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—KRAS—breast cancer	8.5e-06	9.67e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ESR1—breast cancer	8.49e-06	9.66e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CD—breast cancer	8.43e-06	9.6e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FN1—breast cancer	8.38e-06	9.54e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3CA—breast cancer	8.36e-06	9.52e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MDM2—breast cancer	8.33e-06	9.48e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ALB—breast cancer	8.32e-06	9.48e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RAF1—breast cancer	8.3e-06	9.44e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NFKBIA—breast cancer	8.28e-06	9.43e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RELA—breast cancer	8.26e-06	9.4e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ERBB2—breast cancer	8.21e-06	9.34e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NOTCH1—breast cancer	8.2e-06	9.34e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NOS3—breast cancer	8.2e-06	9.33e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CB—breast cancer	8.1e-06	9.22e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MTOR—breast cancer	8.1e-06	9.22e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KIT—breast cancer	8.02e-06	9.13e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—APC—breast cancer	8.02e-06	9.13e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CG—breast cancer	8.02e-06	9.13e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—NOS3—breast cancer	7.96e-06	9.06e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EGF—breast cancer	7.93e-06	9.03e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PTEN—breast cancer	7.82e-06	8.9e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CA—breast cancer	7.81e-06	8.89e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CXCL8—breast cancer	7.78e-06	8.86e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MDM2—breast cancer	7.78e-06	8.85e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RAF1—breast cancer	7.75e-06	8.82e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—HRAS—breast cancer	7.73e-06	8.8e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RELA—breast cancer	7.72e-06	8.78e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—MAPK3—breast cancer	7.68e-06	8.74e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ERBB2—breast cancer	7.67e-06	8.73e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CDKN1B—breast cancer	7.6e-06	8.65e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CB—breast cancer	7.57e-06	8.61e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MTOR—breast cancer	7.57e-06	8.61e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—BRAF—breast cancer	7.54e-06	8.58e-05	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—AKT1—breast cancer	7.52e-06	8.56e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CASP3—breast cancer	7.45e-06	8.48e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL2—breast cancer	7.44e-06	8.47e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL6—breast cancer	7.4e-06	8.43e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CB—breast cancer	7.35e-06	8.37e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IGF1—breast cancer	7.34e-06	8.36e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKT2—breast cancer	7.34e-06	8.35e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—EGFR—breast cancer	7.31e-06	8.32e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PTGS2—breast cancer	7.28e-06	8.29e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CXCL8—breast cancer	7.27e-06	8.28e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCND1—breast cancer	7.25e-06	8.26e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—JUN—breast cancer	7.24e-06	8.24e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—HRAS—breast cancer	7.22e-06	8.22e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CTNNB1—breast cancer	7.18e-06	8.18e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CDKN1B—breast cancer	7.1e-06	8.08e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CD—breast cancer	7.05e-06	8.03e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MMP9—breast cancer	7.04e-06	8.01e-05	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—AKT1—breast cancer	7.02e-06	8e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CDKN1A—breast cancer	7.02e-06	7.99e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PTEN—breast cancer	7e-06	7.97e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CA—breast cancer	6.98e-06	7.95e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SERPINE1—breast cancer	6.97e-06	7.94e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CASP3—breast cancer	6.96e-06	7.92e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL2—breast cancer	6.95e-06	7.91e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL6—breast cancer	6.91e-06	7.87e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—KRAS—breast cancer	6.9e-06	7.86e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MAPK8—breast cancer	6.85e-06	7.79e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—AKT1—breast cancer	6.83e-06	7.77e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCND1—breast cancer	6.77e-06	7.71e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—JUN—breast cancer	6.76e-06	7.7e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CTNNB1—breast cancer	6.71e-06	7.64e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NOS3—breast cancer	6.66e-06	7.58e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MMP9—breast cancer	6.58e-06	7.49e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CDKN1A—breast cancer	6.55e-06	7.46e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTEN—breast cancer	6.54e-06	7.44e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SRC—breast cancer	6.49e-06	7.39e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MAPK8—breast cancer	6.4e-06	7.28e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—AKT1—breast cancer	6.38e-06	7.26e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PTEN—breast cancer	6.35e-06	7.23e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CA—breast cancer	6.34e-06	7.22e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—VEGFA—breast cancer	6.32e-06	7.2e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MDM2—breast cancer	6.32e-06	7.19e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RAF1—breast cancer	6.3e-06	7.17e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RELA—breast cancer	6.27e-06	7.13e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—STAT3—breast cancer	6.26e-06	7.13e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ERBB2—breast cancer	6.23e-06	7.09e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MTOR—breast cancer	6.15e-06	7e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	6.15e-06	7e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SRC—breast cancer	6.06e-06	6.9e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MAPK3—breast cancer	5.98e-06	6.81e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CXCL8—breast cancer	5.91e-06	6.72e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—VEGFA—breast cancer	5.91e-06	6.72e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—HRAS—breast cancer	5.87e-06	6.68e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—STAT3—breast cancer	5.85e-06	6.66e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MYC—breast cancer	5.82e-06	6.62e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TGFB1—breast cancer	5.8e-06	6.61e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	5.77e-06	6.57e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	5.71e-06	6.49e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EGFR—breast cancer	5.69e-06	6.48e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CASP3—breast cancer	5.65e-06	6.43e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL2—breast cancer	5.64e-06	6.43e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL6—breast cancer	5.62e-06	6.39e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MAPK3—breast cancer	5.59e-06	6.36e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CA—breast cancer	5.52e-06	6.28e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCND1—breast cancer	5.5e-06	6.26e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—JUN—breast cancer	5.49e-06	6.25e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	5.45e-06	6.2e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MYC—breast cancer	5.43e-06	6.19e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TGFB1—breast cancer	5.42e-06	6.17e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KRAS—breast cancer	5.37e-06	6.12e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MMP9—breast cancer	5.34e-06	6.08e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	5.32e-06	6.06e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EGFR—breast cancer	5.31e-06	6.05e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTEN—breast cancer	5.31e-06	6.05e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MAPK8—breast cancer	5.2e-06	5.91e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AKT1—breast cancer	5.18e-06	5.9e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KRAS—breast cancer	5.02e-06	5.72e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CA—breast cancer	4.94e-06	5.62e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SRC—breast cancer	4.93e-06	5.61e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—VEGFA—breast cancer	4.8e-06	5.46e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TP53—breast cancer	4.78e-06	5.44e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STAT3—breast cancer	4.75e-06	5.41e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CA—breast cancer	4.61e-06	5.25e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HRAS—breast cancer	4.57e-06	5.2e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MAPK3—breast cancer	4.54e-06	5.17e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—AKT1—breast cancer	4.51e-06	5.13e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CA—breast cancer	4.48e-06	5.1e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TP53—breast cancer	4.46e-06	5.08e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MYC—breast cancer	4.41e-06	5.02e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TGFB1—breast cancer	4.4e-06	5.01e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL6—breast cancer	4.37e-06	4.98e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EGFR—breast cancer	4.32e-06	4.91e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HRAS—breast cancer	4.27e-06	4.86e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL6—breast cancer	4.08e-06	4.65e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KRAS—breast cancer	4.08e-06	4.64e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AKT1—breast cancer	4.03e-06	4.59e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AKT1—breast cancer	3.77e-06	4.29e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	3.75e-06	4.26e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—AKT1—breast cancer	3.66e-06	4.17e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TP53—breast cancer	3.62e-06	4.13e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HRAS—breast cancer	3.47e-06	3.95e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL6—breast cancer	3.32e-06	3.78e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKT1—breast cancer	3.06e-06	3.48e-05	CbGpPWpGaD
